Ibrutinib may increase risk of hypertension

Call for more collaboration between oncologists and cardiologists

Initiation of ibrutinib therapy is associated with an increased risk of hypertension and subsequent cardiovascular events, a study suggests.

Blood pressure monitor reading high

US researchers evaluated the incidence of new or worsening hypertension and major adverse cardiovascular events in 562 consecutive patients treated with ibrutinib for lymphoid malignancies during 2009-2016.

Nearly two-thirds (62%) had hypertension at the time of ibrutinib initiation, and 63% of patients with baseline hypertension were on at least one antihypertensive